(Reuters) – Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company said on Thursday.
(Reporting by Prakhar Srivastava and Kanjyik Ghosh in Bengaluru; Editing by Alan Barona)
